Abeona Therapeutics (ABEO) investor relations material

Executive summary

• ZEVASKYN rollout advanced with expansion to seven qualified treatment centers, including major EB centers like Cincinnati Children's, CHOP, and NewYork-Presbyterian/Columbia, with 12 patients treated since launch and five in Q2 2026.

• Achieved $11.4 million in product revenue for Q2 2026, the first autologous cell-based gene therapy for RDEB, with strong patient and physician interest and ongoing commercialization efforts.

• Operational learnings include logistical complexities, patient health variability, and manufacturing yield challenges, but steady quarterly growth and increased patient onboarding were maintained.

• Net loss for Q2 2026 was $20.2 million ($0.35 per share), compared to net income of $108.8 million in Q2 2025, which included a one-time $152.4 million gain from a priority review voucher sale.

• Cash, equivalents, and short-term investments totaled $146.8 million as of June 30, 2026, expected to fund operations for at least 12 months.

Financial highlights

• Net ZEVASKYN revenue for Q2 2026 was $11.4 million, up 31% quarter-over-quarter from $8.7 million in Q1 2026; six-month revenue was $20.1 million.

• Revenue recognized for four of five Q2 treatments due to one low-yield batch; two treatments overall (including Q3) did not generate revenue.

• R&D expenses were $5.0 million in Q2 2026, down from $9.6 million in Q1 2026, which included a $7.0 million one-time in-licensing cost.

• SG&A expenses were $15.8 million in Q2 2026, down from $19.5 million in Q1 2026, reflecting lower engineering and training costs.

• Q2 2026 cost of sales was $4.2 million; gross margin was 63%.

Outlook and guidance

• Future disclosures will focus on patients treated and net revenue recognized per quarter, aligning with commercial-stage reporting standards.

• Steady-state cadence of one patient per month per QTC expected once all centers are fully operational.

• Gross margins projected to normalize at 85%-90% with higher patient volumes and full operating capacity.

• Management expects continued losses and negative cash flows until ZEVASKYN revenue is sufficient to achieve profitability.

• Current cash and investments are expected to fund operations for at least the next 12 months; additional capital may be needed for full business plan execution.